Precision Biosciences (DTIL) Other financing activities (2018 - 2026)
Precision Biosciences (DTIL) posted quarterly Other financing activities of $662000.0 for Q1 2026, down 35.79% year-over-year from $1.0 million in Q1 2025, and down 35.79% quarter-over-quarter from $1.0 million in Q1 2025.
Precision Biosciences (DTIL) Other financing activities (2018 - 2026) Analysis & Trends
Precision Biosciences (DTIL) has reported Other financing activities for 9 consecutive years, with $662000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other financing activities fell 35.79% year-over-year to $662000.0; the TTM figure through Mar 2026 stood at $662000.0 (down 35.79% YoY), while the FY2025 annual figure was $1.0 million, up 13.92% from the prior year.
- Other financing activities eased to $662000.0 in Q1 2026 per DTIL's latest filing, from $1.0 million in the prior quarter.
- Across five years, Other financing activities topped out at $24.6 million in Q3 2022 and bottomed at $1000.0 in Q4 2023.
- Historically, Other financing activities has averaged $3.5 million across 5 years, with a median of $501000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other financing activities tumbled 99.03% — and 2024, when it jumped 2916.67%.
- Precision Biosciences' Other financing activities stood at $24.6 million in 2022, then tumbled by 100.0% to $1000.0 in 2023, then soared by 90400.0% to $905000.0 in 2024, then gained by 13.92% to $1.0 million in 2025, then plunged by 35.79% to $662000.0 in 2026.
- Business Quant data shows DTIL's Other financing activities at $662000.0 in Q1 2026, $1.0 million in Q1 2025, and $905000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Precision Biosciences | 228.31 Mn | 140.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 662,000.00 |
| Mar 31, 2026 | 662,000.00 |
| Mar 31, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Mar 31, 2024 | 905,000.00 |
| Mar 31, 2024 | 905,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Sep 30, 2022 | 24.62 Mn |
| Sep 30, 2022 | 24.62 Mn |
| Jun 30, 2022 | 38,000.00 |
| Jun 30, 2022 | 38,000.00 |
| Mar 31, 2022 | 340,000.00 |
| Mar 31, 2022 | 340,000.00 |
| Dec 31, 2021 | -28.22 Mn |
| Dec 31, 2021 | -28.22 Mn |
| Sep 30, 2021 | 32.35 Mn |
| Sep 30, 2021 | 32.35 Mn |